HK1255533A1 - 用於檢測大腸癌及進階性腺瘤的蛋白質生物標誌物面板 - Google Patents
用於檢測大腸癌及進階性腺瘤的蛋白質生物標誌物面板Info
- Publication number
- HK1255533A1 HK1255533A1 HK18110284.4A HK18110284A HK1255533A1 HK 1255533 A1 HK1255533 A1 HK 1255533A1 HK 18110284 A HK18110284 A HK 18110284A HK 1255533 A1 HK1255533 A1 HK 1255533A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- colorectal cancer
- protein biomarker
- biomarker panels
- detecting colorectal
- advanced adenoma
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
- G01N2333/70564—Selectins, e.g. CD62
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/99—Isomerases (5.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Primary Health Care (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562146158P | 2015-04-10 | 2015-04-10 | |
US201562160560P | 2015-05-12 | 2015-05-12 | |
US201562165846P | 2015-05-22 | 2015-05-22 | |
US201562196889P | 2015-07-24 | 2015-07-24 | |
US201562239771P | 2015-10-09 | 2015-10-09 | |
PCT/US2016/026773 WO2016164815A1 (en) | 2015-04-10 | 2016-04-08 | Protein biomarker panels for detecting colorectal cancer and advanced adenoma |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1255533A1 true HK1255533A1 (zh) | 2019-08-16 |
Family
ID=55795201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18110284.4A HK1255533A1 (zh) | 2015-04-10 | 2018-08-10 | 用於檢測大腸癌及進階性腺瘤的蛋白質生物標誌物面板 |
Country Status (7)
Country | Link |
---|---|
US (3) | US9689874B2 (zh) |
EP (1) | EP3281016A1 (zh) |
JP (1) | JP2018517892A (zh) |
CA (1) | CA2982169A1 (zh) |
GB (1) | GB2545361B (zh) |
HK (1) | HK1255533A1 (zh) |
WO (1) | WO2016164815A1 (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9141756B1 (en) | 2010-07-20 | 2015-09-22 | University Of Southern California | Multi-scale complex systems transdisciplinary analysis of response to therapy |
KR101937531B1 (ko) * | 2016-09-28 | 2019-01-10 | 국립암센터 | 대장암 진단 장치와 대장암 진단 정보 제공 방법 |
US20180100858A1 (en) | 2016-10-07 | 2018-04-12 | Applied Proteomics, Inc. | Protein biomarker panels for detecting colorectal cancer and advanced adenoma |
US20200237936A1 (en) | 2016-12-14 | 2020-07-30 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
US11139048B2 (en) | 2017-07-18 | 2021-10-05 | Analytics For Life Inc. | Discovering novel features to use in machine learning techniques, such as machine learning techniques for diagnosing medical conditions |
US11062792B2 (en) | 2017-07-18 | 2021-07-13 | Analytics For Life Inc. | Discovering genomes to use in machine learning techniques |
US20200386759A1 (en) * | 2017-12-05 | 2020-12-10 | Discerndx, Inc. | Robust panels of colorectal cancer biomarkers |
JP7102509B2 (ja) * | 2018-04-04 | 2022-07-19 | 富士フイルム株式会社 | 医療文書作成支援装置、医療文書作成支援方法、及び医療文書作成支援プログラム |
US20200011871A1 (en) * | 2018-07-05 | 2020-01-09 | Edp Biotech Corporation | Kits and methods for detecting markers |
US11011276B2 (en) * | 2018-07-09 | 2021-05-18 | Chang Gung Memorial Hospital, Linkou | Method for establishing computer-aided data interpretation model for immune diseases by immunomarkers and visualization |
JP2022550940A (ja) * | 2019-10-01 | 2022-12-06 | エーシー イミューン ソシエテ アノニム | リガンドのスクリーニング用のマイクロ放射性結合アッセイ |
US20210349017A1 (en) * | 2020-05-08 | 2021-11-11 | Caci, Inc. - Federal | Systems and methods for detection of biological agents using infrared spectroscopy |
US20240127444A1 (en) * | 2021-02-16 | 2024-04-18 | Verily Life Sciences Llc | Systems and methods for biomarker detection in digitized pathology samples |
EP4337910A2 (en) * | 2021-05-13 | 2024-03-20 | Arizona Board of Regents on behalf of The University of Arizona | Method of targeted multi-panel approach and tiered a.i. use for differential diagnosis and prognosis |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444879A (en) | 1981-01-29 | 1984-04-24 | Science Research Center, Inc. | Immunoassay with article having support film and immunological counterpart of analyte |
US4517289A (en) | 1982-08-18 | 1985-05-14 | Brigham And Women's Hospital | Monoclonal antibodies for human tissue cross-matching |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4921789A (en) | 1988-04-20 | 1990-05-01 | New England Deaconess Hospital Corporation | Marker for colorectal carcinoma and methods of detecting the same |
US5344760A (en) | 1991-06-03 | 1994-09-06 | Ciba Corning Diagnostics Corp. | Method of cancer detection |
US5786158A (en) | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
US5790761A (en) | 1992-12-11 | 1998-08-04 | Heseltine; Gary L. | Method and apparatus for the diagnosis of colorectal cancer |
AU6350894A (en) | 1993-03-05 | 1994-09-26 | Clifford W. Schweinfest | Colon mucosa gene having down-regulated expression in colon adenomas and adenocarcinomas |
US7229770B1 (en) | 1998-10-01 | 2007-06-12 | The Regents Of The University Of California | YKL-40 as a marker and prognostic indicator for cancers |
DK85193D0 (da) | 1993-07-16 | 1993-07-16 | Cancerforskningsfondet Af 1989 | Suppression of inhibitors |
US6316208B1 (en) | 1994-01-07 | 2001-11-13 | Memorial Sloan-Kettering Cancer Center | Methods for determining isolated p27 protein levels and uses thereof |
WO1997007236A1 (en) | 1995-08-18 | 1997-02-27 | Landry Donald W | Detection of organic compounds through regulation of antibody-catalyzed reactions |
US5800347A (en) | 1995-11-03 | 1998-09-01 | The General Hospital Corporation | ROC method for early detection of disease |
NO954667D0 (no) | 1995-11-17 | 1995-11-17 | Dagfinn Oegreid | Fremgangsmåte til deteksjon av Ki-ras mutasjoner |
US5983211A (en) | 1996-01-24 | 1999-11-09 | Heseltine; Gary L. | Method and apparatus for the diagnosis of colorectal cancer |
US6242212B1 (en) | 1996-02-09 | 2001-06-05 | Thomas Jefferson University | Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins |
GB9810040D0 (en) | 1998-05-11 | 1998-07-08 | Univ Nottingham | Blood borne tumour markers |
US6303372B1 (en) | 1998-06-12 | 2001-10-16 | Chiron Corporation | cDNA molecule encoding human CIF130 |
GB9827228D0 (en) | 1998-12-10 | 1999-02-03 | Univ Nottingham | Cancer detection method and reagents |
AU767833B2 (en) | 1999-01-10 | 2003-11-27 | Exact Sciences Corporation | Methods of detecting colorectal disease |
US7153700B1 (en) | 1999-03-26 | 2006-12-26 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for diagnosing and predicting the behavior of cancer |
ES2244417T3 (es) | 1999-04-09 | 2005-12-16 | Rigshospitalet | Inhibidor de tejido de metaloproteasa de matriz tipo-1 (timp-1) como un marcador de cancer. |
US20010041365A1 (en) | 2000-01-10 | 2001-11-15 | Michael Laposata | Methods for monitoring alcohol consumption |
US6322986B1 (en) | 2000-01-18 | 2001-11-27 | Albany Medical College | Method for colorectal cancer prognosis and treatment selection |
US7301016B2 (en) | 2000-03-07 | 2007-11-27 | Millennium Pharmaceuticals, Inc. | Human transferase family members and uses thereof |
US7577683B2 (en) | 2000-06-08 | 2009-08-18 | Ingenuity Systems, Inc. | Methods for the construction and maintenance of a knowledge representation system |
US6531283B1 (en) | 2000-06-20 | 2003-03-11 | Molecular Staging, Inc. | Protein expression profiling |
DE60142356D1 (de) | 2000-07-18 | 2010-07-22 | Millennium Pharm Inc | 18480 humane proteinkinasemoleküle und ihre verwendungen |
US6706506B2 (en) | 2000-07-24 | 2004-03-16 | Cornell Research Foundation, Inc. | Detection of epithelial cell cancers and precancerous conditions |
AU2001297575A1 (en) | 2000-11-08 | 2002-10-08 | Millennium Pharmaceuticals, Inc. | 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof |
US7312086B2 (en) | 2000-12-07 | 2007-12-25 | Bristol-Myers Squibb Company | Methods of diagnosing colon adenocarcinoma using the human g-protein coupled receptor hgprbmy23 |
EP1430145B1 (en) | 2001-03-23 | 2013-01-02 | Yeda Research And Development Co., Ltd. | Methods for determing a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a dna repair enzyme and a cancer |
BR0209646A (pt) | 2001-05-16 | 2006-10-10 | Novartis Ag | genes expressos em cáncer de mama como alvos de prognósticos e terapêuticos |
US7031846B2 (en) | 2001-08-16 | 2006-04-18 | Affymetrix, Inc. | Method, system, and computer software for the presentation and storage of analysis results |
EP1430071B1 (en) | 2001-09-07 | 2011-04-06 | The Johns Hopkins University School Of Medicine | Secreted and cell surface genes expressed in benign and malignant colorectal tumors |
US20040018973A1 (en) | 2002-01-25 | 2004-01-29 | University Of Pittsburgh | Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof |
US20030186248A1 (en) | 2002-03-29 | 2003-10-02 | Erlander Mark G. | Interpreting cytological specimens via molecular histological signatures |
EP1367395A1 (de) | 2002-05-02 | 2003-12-03 | B.R.A.H.M.S Aktiengesellschaft | Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern |
AU2003268905A1 (en) | 2002-05-21 | 2003-12-02 | Mtm Laboratories Ag | G - protein coupled receptor marker molecules associated with colorectal lesions |
US20050153382A1 (en) | 2002-06-06 | 2005-07-14 | Chengdu Kuachang Science And Technology Co., Ltd. | Biochip kit comprising biochip based on antigen-antibody reactions, and its usage |
US7425700B2 (en) | 2003-05-22 | 2008-09-16 | Stults John T | Systems and methods for discovery and analysis of markers |
ES2905579T3 (es) | 2003-07-10 | 2022-04-11 | Genomic Health Inc | Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama |
DE102004037860A1 (de) | 2004-08-04 | 2006-03-16 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen |
WO2006015616A1 (en) | 2004-08-13 | 2006-02-16 | Indivumed Gmbh | Use of transthyretin as a biomarker for colorectal adenoma and/or carcinoma; method for detection and test system |
US20060105419A1 (en) | 2004-08-16 | 2006-05-18 | Biosite, Inc. | Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions |
WO2006047482A2 (en) | 2004-10-22 | 2006-05-04 | Redpath Integrated Pathology, Inc. | Method for determining the diagnosis, malignant potential, and biologic behavior of pancreatic cysts using cyst aspirate |
US9109256B2 (en) | 2004-10-27 | 2015-08-18 | Esoterix Genetic Laboratories, Llc | Method for monitoring disease progression or recurrence |
WO2006094149A2 (en) | 2005-03-01 | 2006-09-08 | Exact Sciences Corporation | Methods and compositions for detecting adenoma |
US9075062B2 (en) | 2005-03-22 | 2015-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Identification of biomarkers by serum protein profiling |
ES2717627T3 (es) | 2005-07-29 | 2019-06-24 | Siemens Healthcare Diagnostics Inc | Métodos, kits, sistemas y bases de datos relacionados con enfermedades neoplásicas |
SG182169A1 (en) | 2005-09-12 | 2012-07-30 | Phenomenome Discoveries Inc | Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites |
CN101263391A (zh) | 2005-09-12 | 2008-09-10 | 菲诺梅诺米发现公司 | 通过测量维生素e-相关的代谢物诊断结肠直肠癌和卵巢癌的方法 |
EP1937831B1 (en) | 2005-09-27 | 2012-08-01 | University of Saskatchewan | Use of n-myristoyltransferase on non-tumor tissue for cancer diagnosis |
EP1946118A4 (en) | 2005-11-10 | 2009-01-21 | Aurelium Biopharma Inc | TISSUE DIAGNOSIS OF BREAST CANCER |
GB0524190D0 (en) | 2005-11-28 | 2006-01-04 | Helse Stavanger Hf | Method |
ES2277785B1 (es) | 2005-12-21 | 2008-06-16 | Oryzon Genomics, S.A. | Metodo de analisis de expresion diferencial en cancer colorectal. |
US20090035801A1 (en) | 2005-12-27 | 2009-02-05 | Power3 Medical Products, Inc. | Twelve (12) protein biomarkers for diagnosis and early detection of breast cancer |
EP2412822A1 (en) | 2006-01-11 | 2012-02-01 | Genomic Health, Inc. | Gene expression markers for colorectal cancer prognosis |
WO2007090125A2 (en) | 2006-01-30 | 2007-08-09 | Introgen Therapeutics, Inc. | Prognostic factors for anti-hyperproliferative disease gene therapy |
WO2007127002A2 (en) | 2006-03-31 | 2007-11-08 | Cell Signaling Technology, Inc. | Protein markers of responsiveness to type iii receptor tyrosine kinase inhibitors |
WO2007149456A2 (en) | 2006-06-19 | 2007-12-27 | Vanderbilt University | Methods and compositions for diagnostic and therapeutic targeting of cox-2 |
US7811778B2 (en) | 2006-09-06 | 2010-10-12 | Vanderbilt University | Methods of screening for gastrointestinal cancer |
WO2008073858A2 (en) | 2006-12-08 | 2008-06-19 | The Johns Hopkins University | Cancer chemoprevention strategy based on loss of imprinting of igf2 |
BRPI0806437A2 (pt) | 2007-01-26 | 2011-09-06 | Univ Lousville Res Foundation Inc | métodos de detecção de auto-anticorpos para diagnóstico e caracterização de distúrbio |
WO2008116178A2 (en) | 2007-03-21 | 2008-09-25 | Vanderbilt University | Systems and methods for diagnosis and prognosis of colorectal cancer |
CA2688558A1 (en) | 2007-06-04 | 2009-03-26 | Diagnoplex | Biomarker combinations for colorectal cancer |
DE102007034993A1 (de) | 2007-07-26 | 2009-01-29 | Hanna Diehl | Lösliches Cadherin 17 für die Diagnose und Risikostratifizierung von Darmtumor oder Darmkrebs |
WO2009015299A1 (en) | 2007-07-26 | 2009-01-29 | California Pacific Medical Center | Method to predict or diagnose a gastrointestinal disorder or disease |
WO2009040782A2 (en) | 2007-09-28 | 2009-04-02 | Royal College Of Surgeons In Ireland | A method of assessing colorectal cancer status in an individual |
ATE521894T1 (de) | 2007-11-20 | 2011-09-15 | Hoffmann La Roche | Verfahren zur beurteilung von kolorektalem krebs anhand einer stuhlprobe durch verwendung einer marker-kombination aus calprotectin und einem hämoglobin/haptoglobin-komplex |
KR101058753B1 (ko) | 2007-11-22 | 2011-08-24 | 한국생명공학연구원 | 대장암 마커로서의 esm-1 유전자 및 이를 이용한대장암의 진단 및 치료에의 용도 |
BRPI0820793A2 (pt) | 2007-12-10 | 2015-06-16 | Hoffmann La Roche | Seprase como marcador de câncer |
JP5591711B2 (ja) * | 2007-12-10 | 2014-09-17 | エフ.ホフマン−ラ ロシュ アーゲー | 結腸直腸癌のためのマーカーパネル |
US20110052581A1 (en) | 2008-02-08 | 2011-03-03 | Poniard Pharmaceuticals Inc. | Use of picoplatin and cetuximab to treat colorectal cancer |
CN102027128A (zh) | 2008-02-11 | 2011-04-20 | 哈达斯特医学服务与开发有限公司 | 作为癌症标志物的结肠癌相关的转录物1(ccat-1) |
JPWO2009107170A1 (ja) | 2008-02-29 | 2011-06-30 | 学校法人日本大学 | 抗crp抗体及びその利用 |
EP2255017A1 (en) | 2008-03-18 | 2010-12-01 | Epigenomics AG | A method for optimizing and validating an assay for determining the presence or absence of a medical condition |
JP2011515478A (ja) | 2008-03-25 | 2011-05-19 | シェーリング コーポレイション | 結腸直腸がんを処置または予防するための方法 |
US8921074B2 (en) | 2008-04-10 | 2014-12-30 | Genenews, Inc. | Method and apparatus for determining a probability of colorectal cancer in a subject |
WO2009138392A1 (en) | 2008-05-14 | 2009-11-19 | ETH Zürich | Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith |
EP2796878A1 (en) | 2008-05-23 | 2014-10-29 | Biocartis NV | New biomarkers for diagnosis, prediction and/or prognosis of sepsis and uses thereof |
CA2731216A1 (en) | 2008-07-18 | 2010-01-21 | Oragenics, Inc. | Compositions for the detection and treatment of colorectal cancer |
EP2169077A1 (en) | 2008-09-19 | 2010-03-31 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Methods and compositions for diagnosing an adenocarcinoma |
US20100204299A1 (en) | 2009-02-11 | 2010-08-12 | Daniel Regnier | C-cbl and antagonists thereof for the treatment and diagnosis of cancer |
JP2012517607A (ja) | 2009-02-20 | 2012-08-02 | オンコノム,インコーポレイテッド | 大腸癌の診断及び予後判定のための用具セット及び方法 |
JP5384672B2 (ja) | 2009-02-24 | 2014-01-08 | エフ.ホフマン−ラ ロシュ アーゲー | 癌のマーカーとしてのs−ErbB−3の使用 |
KR20120105444A (ko) | 2009-10-15 | 2012-09-25 | 오클라호마 메디컬 리써치 화운데이션 | 염증성 질병의 활성 측정 및 모니터링을 위한 바이오마커 및 방법 |
US7736861B1 (en) | 2009-10-19 | 2010-06-15 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
CA2781408A1 (en) * | 2009-11-20 | 2011-05-26 | University Of Louisville Research Foundation Inc. | Biomarkers of cancer |
ES2633111T3 (es) | 2010-03-26 | 2017-09-19 | Hongzhi Zou | Métodos y materiales para detectar neoplasia colorrectal |
US10119959B2 (en) | 2010-06-25 | 2018-11-06 | The Board Of Trustees Of The Leland Stanford Junior University | Method of assaying an individual for immune impairment |
GB201012590D0 (en) | 2010-07-27 | 2010-09-08 | Queen Mary & Westfield College | Methods for diagnosing cancer |
US8389684B2 (en) | 2010-09-13 | 2013-03-05 | Tsinghua University | Tumor biomarker |
ES2545515T3 (es) | 2011-01-28 | 2015-09-11 | F. Hoffmann-La Roche Ag | Biomarcadores combinatorios para aplicaciones clínicas en la gestión del paciente con cáncer de pulmón |
US20140141986A1 (en) | 2011-02-22 | 2014-05-22 | David Spetzler | Circulating biomarkers |
EP2744919A4 (en) | 2011-08-19 | 2015-04-08 | Myriad Genetics Inc | GENE SIGNATURES FOR PROGNOSIS OF LUNG CANCER AND SELECTION OF THERAPY |
WO2013152989A2 (en) | 2012-04-10 | 2013-10-17 | Eth Zurich | Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer |
US20150141273A1 (en) * | 2012-04-26 | 2015-05-21 | Stichting Vu-Vumc | Biomarkers |
CA2893158A1 (en) | 2012-11-30 | 2014-06-05 | Applied Proteomics, Inc. | Method for evaluation of presence of or risk of colon tumors |
-
2016
- 2016-04-08 JP JP2017552968A patent/JP2018517892A/ja active Pending
- 2016-04-08 GB GB1703773.0A patent/GB2545361B/en not_active Expired - Fee Related
- 2016-04-08 CA CA2982169A patent/CA2982169A1/en not_active Abandoned
- 2016-04-08 US US15/094,767 patent/US9689874B2/en active Active
- 2016-04-08 WO PCT/US2016/026773 patent/WO2016164815A1/en unknown
- 2016-04-08 EP EP16717530.6A patent/EP3281016A1/en not_active Withdrawn
-
2017
- 2017-06-21 US US15/629,593 patent/US20170370937A1/en not_active Abandoned
-
2018
- 2018-08-10 HK HK18110284.4A patent/HK1255533A1/zh unknown
-
2019
- 2019-05-01 US US16/400,257 patent/US20190257835A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170370937A1 (en) | 2017-12-28 |
GB2545361B (en) | 2018-01-24 |
GB2545361A (en) | 2017-06-14 |
WO2016164815A1 (en) | 2016-10-13 |
US20160299144A1 (en) | 2016-10-13 |
GB201703773D0 (en) | 2017-04-26 |
US20190257835A1 (en) | 2019-08-22 |
JP2018517892A (ja) | 2018-07-05 |
CA2982169A1 (en) | 2016-10-13 |
US9689874B2 (en) | 2017-06-27 |
EP3281016A1 (en) | 2018-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1255533A1 (zh) | 用於檢測大腸癌及進階性腺瘤的蛋白質生物標誌物面板 | |
IL276481B (en) | Anti-b7-h1 and anti-ctla-4 antibodies for the treatment of non-small cell lung cancer | |
HK1248285A1 (zh) | 判定癌症狀態之方法及系統 | |
HK1246828A1 (zh) | 用於檢測癌症的生物標志物組 | |
HK1217219A1 (zh) | 結直腸癌生物標誌物 | |
IL247987A0 (en) | Protein biomarker profiles for colon tumor detection | |
GB201808422D0 (en) | Protein biomarker panels for detecting colorectal cancer and advanced adenoma | |
IL253710A0 (en) | Biomarkers for pancreatic cancer, and kits and methods to detect them | |
EP3647788A4 (en) | BIOMARKER FOR THE DETECTION OF COLORECTAL CANCER | |
IL267315A (en) | Methods of determining colorectal cancer status in an individual | |
SG11201701875YA (en) | Methods for detecting ovarian cancer | |
IL264359A (en) | Combined test for colon cancer | |
EP3134545A4 (en) | Method and biomarker for detecting cancer | |
EP2972376A4 (en) | Methods for determining prognosis of colorectal cancer | |
HK1249134A1 (zh) | 結直腸癌相關疾病的生物標誌物 | |
IL257514A (en) | A method for detecting cancer | |
EP3258923A4 (en) | METHODS AND SUBSTANCES FOR EVALUATING RESPONSE TO CHEMOTHERAPY AND TREATING CANCER | |
PL3545109T3 (pl) | Sposób identyfikacji in vitro gruczolaków jelita grubego lub raka jelita grubego | |
GB201411393D0 (en) | Agents and methods for determining colorectal cancer status | |
GB201604809D0 (en) | Method for detecting cancer | |
GB201604813D0 (en) | Methods for detecting cancer | |
GB201508185D0 (en) | Methods of detecting and predicting cancer | |
AU2015903361A0 (en) | Cancer detection method |